Medica Weight Loss: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Medica Weight Loss’ website, https://medicaweightloss.com, FDA Establishment Identifier (FEI) 3044019522, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “medica weight loss” on the pictured label, suggesting Medica Weight Loss is the compounder of those drugs when in fact it is not.”

2. 2

   “2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Clinical studies and FDA approval support [semaglutide’s] safety and effectiveness….” “Tirzepatide is FDA-approved….” Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

3. 3

   “3. Your website claims that the compounded drug products it offers are sourced from an “FDA-approved pharmacy.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities. Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

medicaweightloss.com returned a live site on 2026-08-09 titled "Semaglutide & Tirzepatide Weight Loss Injections | Medical", advertising "Plans starting at $197" with an eligibility check and a working account login — an operating storefront.

There is a real difference between a page that invites you to infer approval and a page that simply asserts it, and this one asserts it: "Tirzepatide is FDA-approved...." That sentence is true of Mounjaro and Zepbound, the branded products. It is not true of the compounded tirzepatide being sold beside it, and the letter's reply is one line with nothing left to interpret. The same goes for "Clinical studies and FDA approval support safety and effectiveness" — the studies exist, but they were run on the approved product. Borrowing their conclusion for a different, unapproved one is the move FDA objected to. That matters when a price is on the screen, because approval is the shortcut most people use to stop evaluating and start buying. The label finding is worth a second look as well: the vial read the company's name in lower case, and FDA still counted it as a claim to have compounded the drug. Typography does not create distance. None of this concerns whether the medicine is safe or whether $197 is a fair price — it concerns whether the strongest sentence on the page was one the company was entitled to write.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Medica Weight Loss failed to respond.